Overview A condition where the eye’s optic nerve, which provides information to the brain, is damaged with or without raised ...

Young people in the UK are the biggest consumers of energy drinks for their age group in Europe. Here’s what we all need to ...

The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

They administered the xylazine-based conjugates to mice and monitored how the mice moved and breathed when they were later ...

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for ...

In a study published in Cell Host & Microbe, a research team has demonstrated the causal link between microbial factors and ...

Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201 ...

In this study, researchers first revealed that α 2A-adrenergic receptor (ADRA2A) is a highly expressed G-protein-coupled receptor (GPCR) in ISCs. Through PRESTO-Tango and BRET2 GPCR assays ...

Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism (1). The research paper validates the ...

Explore Ohio's dynamic biotech scene, where leading companies drive innovation and contribute to healthcare advancements.

Onyda XR, a centrally acting alpha 2-adrenergic agonist, was approved based on adequate and well-controlled studies of clonidine hydrochloride extended-release tablets. The non-stimulant treatment is ...